Related references
Note: Only part of the references are listed.ADAM-17: a novel therapeutic target for triple negative breast cancer
P. M. McGowan et al.
ANNALS OF ONCOLOGY (2013)
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
Anneleen Daemen et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells
Hsiao-Ching Chuang et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer
Anne-Renee Hartman et al.
CANCER (2012)
HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair
Somaira Nowsheen et al.
CANCER RESEARCH (2012)
Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
Xuesong Liu et al.
CLINICAL CANCER RESEARCH (2012)
Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
Anand G. Patel et al.
CLINICAL CANCER RESEARCH (2012)
Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells
Somaira Nowsheen et al.
PLOS ONE (2012)
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Yasir H. Ibrahim et al.
CANCER DISCOVERY (2012)
Poly(ADP-Ribose) Polymerase (PARP) Inhibitors: Exploiting a Synthetic Lethal Strategy in the Clinic
Timothy A. Yap et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
Yvette Drew et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors
Patryk Moskwa et al.
MOLECULAR CELL (2011)
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Karen A. Gelmon et al.
LANCET ONCOLOGY (2011)
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Neil Johnson et al.
NATURE MEDICINE (2011)
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.
Joyce O'Shaughnessy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
Kedar Hastak et al.
CANCER RESEARCH (2010)
Poly(ADP-Ribose) Polymerase Inhibition: Targeted Therapy for Triple-Negative Breast Cancer
Carey K. Anders et al.
CLINICAL CANCER RESEARCH (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
Raga Krishnakumar et al.
MOLECULAR CELL (2010)
Making the best of PARP inhibitors in ovarian cancer
Susana Banerjee et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
PARP inhibition: PARP1 and beyond
Michele Rouleau et al.
NATURE REVIEWS CANCER (2010)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity
Linda Hughes et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Detection of almplifiable mRNA extracellular to insulin-producing cells: Potential for predicting beta cell mass and, function
Sweta Rani et al.
CLINICAL CHEMISTRY (2007)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
Share Paper
